Portugal
Key Insights
- 1
No psychedelic therapy is approved for routine patient access in Portugal; possession is decriminalised since 1 July 2001, but medical access remains limited to standard licensed medicines and clinical trials. ([eldd.emcdda.europa.eu](https://eldd.emcdda.europa.eu/attachements.cfm/att_5741_EN_Decriminalisation_Legal_Approaches.pdf?utm_source=openai))
- 2
Portugal has 3 psychedelic trials in the database, 1 active; psilocybin dominates current activity, with esketamine and placebo only in the historical mix. ([clinicaltrials.gov](https://clinicaltrials.gov/show/NCT06650800?utm_source=openai))
- 3
A Lisbon-linked psilocybin neuroimaging study launched in 2024, making Portugal a visible site for treatment-resistant depression research. ([clinicaltrials.gov](https://clinicaltrials.gov/show/NCT06650800?utm_source=openai))
- 4
Momentum now centres on psilocybin, with the only active study still running and Portugal’s public-health drug-policy model giving researchers a permissive backdrop. ([clinicaltrials.gov](https://clinicaltrials.gov/show/NCT06650800?utm_source=openai))
Reimbursed Care Access
Portugal has a decriminalised approach to personal drug possession (Law 30/2000) while maintaining statutory control over most classic psychedelics under the national drug schedules (Decree‑Law n.º 15/93). Licensed pharmaceutical psychedelics have begun to enter regulated medical pathways (notably esketamine/Spravato, with Infarmed public‑funding evaluation decisions in 2025), while other compounds remain available only within regulated clinical research or, in practice, via private/off‑label clinic programmes subject to medical oversight and no routine public reimbursement.
Quick Indicators
Research Events
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Portugal.